Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
Provided By GlobeNewswire
Last update: Aug 1, 2024
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately.
